Clinical trial
Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia
NCT00060892 · AnGes USA, Inc., Industry · Completed
Key facts
| NCT number | NCT00060892 |
|---|---|
| Title | Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia |
| Official title | A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Leg Ischemia |
| Lead sponsor | AnGes USA, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia |
| Intervention type | Genetic |
| Interventions | HGF plasmid |
| Enrollment | 104 |
| Start date | Apr 1, 2003 |
| Primary completion | May 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | May 16, 2003 |
| Last update posted | Jan 11, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: